Kala Bio Inc (KALA)
7.08
+0.16
(+2.31%)
USD |
NASDAQ |
May 08, 16:00
6.80
-0.28
(-3.95%)
Pre-Market: 20:00
Kala Bio 1 Year Total Returns (Daily): -55.19% for May 8, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
Date | Value |
---|---|
May 08, 2024 | -55.19% |
May 07, 2024 | -54.83% |
May 06, 2024 | -54.70% |
May 03, 2024 | -54.76% |
May 02, 2024 | -55.53% |
May 01, 2024 | -55.66% |
April 30, 2024 | -56.75% |
April 29, 2024 | -56.56% |
April 26, 2024 | -57.94% |
April 25, 2024 | -60.18% |
April 24, 2024 | -59.37% |
April 23, 2024 | -58.31% |
April 22, 2024 | -59.81% |
April 19, 2024 | -57.97% |
April 18, 2024 | -56.90% |
April 17, 2024 | -58.98% |
April 16, 2024 | -58.81% |
April 15, 2024 | -57.91% |
April 12, 2024 | -58.79% |
April 11, 2024 | -57.75% |
April 10, 2024 | -46.97% |
April 09, 2024 | -46.30% |
April 08, 2024 | -44.78% |
April 05, 2024 | -44.57% |
April 04, 2024 | -44.24% |
Date | Value |
---|---|
April 03, 2024 | -46.34% |
April 02, 2024 | -46.91% |
April 01, 2024 | -46.91% |
March 28, 2024 | -49.30% |
March 27, 2024 | -48.05% |
March 26, 2024 | -49.39% |
March 25, 2024 | -49.20% |
March 22, 2024 | -43.61% |
March 21, 2024 | -47.19% |
March 20, 2024 | -37.00% |
March 19, 2024 | -44.30% |
March 18, 2024 | -44.44% |
March 15, 2024 | -54.88% |
March 14, 2024 | -54.53% |
March 13, 2024 | -50.20% |
March 12, 2024 | -59.84% |
March 11, 2024 | -58.51% |
March 08, 2024 | -65.61% |
March 07, 2024 | -61.03% |
March 06, 2024 | -66.47% |
March 05, 2024 | -55.37% |
March 04, 2024 | -54.27% |
March 01, 2024 | -23.08% |
February 29, 2024 | -29.12% |
February 28, 2024 | -29.07% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-95.32%
Minimum
Nov 08 2022
158.3%
Maximum
Jun 16 2020
-28.94%
Average
-54.23%
Median
May 12 2021
1 Year Total Returns (Daily) Benchmarks
CEL-SCI Corp | -44.40% |
AIM ImmunoTech Inc | -12.35% |
IGC Pharma Inc | 53.98% |
NovaBay Pharmaceuticals Inc | -90.82% |
Protalix BioTherapeutics Inc | -62.50% |